Eli Lilly â€™s monoclonal antibody treatment for Covid 19 , bamlanivimab , got interim authorization from Health Canada Friday , according to a company news release . 
The treatment is approved for use in Canada in adults and children older than 12 with a mild to moderate case of Covid 19 who are at high risk of progressing to more severe disease . 
This is the second authorization for bamlanivimab . 
The US Food and Drug Administration gave it an emergency use authorization Nov . 9 . 
The treatment was created through a partnership with the help of the Canadian biotechnology company Ab Cellera . 
